weight loss glp 1 agonists Study finds GLP-1 receptor target fat over muscle for GLP-1 medications for weight loss
Description
References Batterham, R
In 2023, Eli Lilly entered the market with Zepbound (tirzepatide), boasting over 20% weight loss at 72 weeks and a slightly lower price
The vial presentation of Zepbound provides flexibility for healthcare providers and patients
Drugs affected by gastric emptying Medications are partially digested in the stomach before being emptied into the small intestine, where most drugs are absorbed
Side effects remain one of the primary drivers of discontinuation
